Filters
In the treatment of patients with unresectable hepatocellular carcinoma (HCC), the addition of tiragolumab to atezolizumab plus bevacizumab yields meaningful improvements in antitumour response and disease control, according to data from an open-label phase 1b–2 study.
A novel vaccine that targets HPV type 16 (HPV16) has shown clinical activity against HPV16-positive cervical intraepithelial neoplasia grade 3 (CIN3) in a phase II trial, substantially reducing lesion size.
Treatment with the combination of sacubitril-valsartan plus spironolactone during hospitalization for acute decompensated heart failure (ADHF) does not lead to a substantially higher incidence of adverse drug reactions (ADRs), a study has shown.
Treatment with the combination of the small molecule Janus kinase 1/2 inhibitor baricitinib plus phototherapy may help reduce disease activity and induce repigmentation in adults with extensive and active nonsegmental vitiligo, according to the results of a phase II study.
Ensuring antipsychotic medication use as prescribed may be crucial for reducing the risk of suicidality among patients with schizophrenia, according to a study.
The use of clozapine appears to slightly increase the risk of haematological malignancy (HM) among patients with schizophrenia compared with olanzapine use, suggests a study.
In the treatment of patients with mild ischaemic stroke, prourokinase is not necessarily better than standard of care in terms of improving functional outcomes, although both have a similar safety profile, according to a study.
A new patch that adheres to the skin and delivers two active ingredients holds promise in the treatment of psoriasis, reducing the need to apply topical medications to once a day and potentially improving adherence.
Patients with a history of seizures do not appear to be at an increased risk of cefepime-induced neurotoxicity (CIN), according to a study.
For patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), continued use of metformin for at least 6 months when eGFR falls below 30 mL/min/1.73m2 appears to yield a small but significant decrease in all-cause mortality, according to a nationwide observational cohort study.
